2 results
Approved WMOCompleted
Primary objective: To compare progression-free survival (PFS) as assessed by blinded, central review between patients randomized to niraparib versus physician*s choice. Key secondary objective: To compare overall survival between patients randomized…
Approved WMORecruiting
To investigate whether enhanced expression of growth factor receptors (FGF-R, PDGF-R and VEGF-R) and increasedvascular cell proliferation in the lung of IPF or PAH patients can be assessed using [11C]-Nintedanib or [18F]-FLTPET/CT imaging.